KLok的个人主页 - 老虎社区

KLok

KLok

暂无个人介绍

IP属地：未知

0关注

49粉丝

0主题

0勋章

2021-06-15

$Apple(AAPL)$[看涨] [看涨] [看涨]

2021-05-23

$Apple(AAPL)$[捂脸] [流泪] when is it going to move up????

2021-07-29

$Pfizer(PFE)$[看涨] [看涨] [看涨]

2021-06-23

$Pfizer(PFE)$[看涨] [看涨] [看涨]

2021-11-10

Bad news for the market.

Kimbal Musk cashed out $109 million of Tesla stock just before Elon's tweets whacked the share price

2021-08-22

[惊讶] [看涨] [看涨] [看涨]

抱歉，原内容已删除

2021-08-18

$Intel(INTC)$[捂脸] [捂脸] [喷血]

2021-07-02

$Pfizer(PFE)$[贱笑] [贱笑] [贱笑]

2021-06-13

$Apple(AAPL)$[冷漠] [冷漠] [冷漠]

2021-11-14

Good news.....

Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.

2021-11-10

$Tesla Motors(TSLA)$[看涨] [看涨] [看涨]

2021-09-05

$Pfizer(PFE)$[看涨] [看涨] [看涨]

2021-08-16

$Intel(INTC)$[捂脸] [喷血]

2021-08-11

$Intel(INTC)$[看涨] [看涨] [看涨]

2021-07-28

$Pfizer(PFE)$[看涨] [看涨] [看涨] fingers crossed....

2021-05-21

[无语]

Apple: Victim Of Its Own Success

2021-05-06

$Pfizer(PFE)$[笑哭]

2021-11-12

$Tesla Motors(TSLA)$[看涨] [看涨] [看涨]

2021-11-05

Good news.

抱歉，原内容已删除

2021-09-21

$Intel(INTC)$time to buy???[白眼]

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3582450584533032,"uuid":"3582450584533032","gmtCreate":1619400809948,"gmtModify":1620044598018,"name":"KLok","pinyin":"klok","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":49,"headSize":0,"tweetSize":327,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.13","exceedPercentage":"80.90%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.15%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":698002689,"gmtCreate":1640254446848,"gmtModify":1640254447499,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Well done","listText":"Well done","text":"Well done","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698002689","repostId":"691779338","repostType":1,"repost":{"id":691779338,"gmtCreate":1640251927419,"gmtModify":1640251927419,"author":{"id":"3463112040984428","authorId":"3463112040984428","name":"秋虫语冰","avatar":"https://static.tigerbbs.com/97260ad2eb80155b4228f8f6ea0f6877","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/OPT/TSLA 20211223 1000.0 CALL\">$TSLA 20211223 1000.0 CALL$&nbsp;</a>盘前表现不错，马总给力！","listText":"<a href=\"https://laohu8.com/OPT/TSLA 20211223 1000.0 CALL\">$TSLA 20211223 1000.0 CALL$&nbsp;</a>盘前表现不错，马总给力！","text":"$TSLA 20211223 1000.0 CALL$ 盘前表现不错，马总给力！","images":[{"img":"https://static.tigerbbs.com/b1d5db726f58b7069f8819b50223e000","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691779338","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":503,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699844653,"gmtCreate":1639786116595,"gmtModify":1639786117166,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[Call]&nbsp;[Call]&nbsp;[Call]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[Call]&nbsp;[Call]&nbsp;[Call]&nbsp;","text":"$Tesla Motors(TSLA)$[Call] [Call] [Call]","images":[{"img":"https://static.tigerbbs.com/372e25bfd36cdb3dfda4fbe5859388e9","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699844653","isVote":1,"tweetType":1,"viewCount":526,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":875755194,"gmtCreate":1637705600615,"gmtModify":1637705600846,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good news....","listText":"Good news....","text":"Good news....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875755194","repostId":"2185338899","repostType":2,"isVote":1,"tweetType":1,"viewCount":666,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875353784,"gmtCreate":1637617783402,"gmtModify":1637617828868,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good news...","listText":"Good news...","text":"Good news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875353784","repostId":"2185877459","repostType":2,"isVote":1,"tweetType":1,"viewCount":443,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876368641,"gmtCreate":1637273621521,"gmtModify":1637273621789,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Bad news for Tesla.&nbsp;","listText":"Bad news for Tesla.&nbsp;","text":"Bad news for Tesla.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876368641","repostId":"2184994048","repostType":2,"repost":{"id":"2184994048","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1637303014,"share":"https://www.laohu8.com/m/news/2184994048?lang=&edition=full","pubTime":"2021-11-19 14:23","market":"us","language":"en","title":"In Los Angeles, Tesla's rivals roll out larger, cheaper electric SUVs","url":"https://stock-news.laohu8.com/highlight/detail?id=2184994048","media":"Reuters","summary":"LOS ANGELES, Nov 18 (Reuters) - Automakers chasing electric vehicle leader Tesla Inc revealed new, m","content":"<p>LOS ANGELES, Nov 18 (Reuters) - Automakers chasing electric vehicle leader Tesla Inc&nbsp;revealed new, more affordable and larger electric sport utility vehicles at the Los Angeles Auto Show, racing into one of the fastest-growing segments of the U.S. market.</p>\n<p>Kia Motors&nbsp;called out Tesla by name at the show, announcing that its upcoming electric crossover EV6 beat Tesla’s previous record for the shortest charging time, while driving across the United States, by more than five hours.</p>\n<p>Kia and affiliate Hyundai Motor&nbsp;also unveiled large, three-row electric sport utility vehicle concepts, EV9 and SEVEN. These models are expected go into production around 2024, two persons familiar with the matter said.</p>\n<p>\"They (Tesla) have strong sales and they have a very good public awareness. But not everything is for everybody. So there should also always be an alternative,\" said Michael McHale, Kia's brand experience director.</p>\n<p>The focus on electric SUVs reflects the strong preference among U.S. consumers for SUVs, which typically sell for higher prices than similar-sized sedans. Large SUVs account for the top-selling segment in the U.S. market, industry executives and analysts have said.</p>\n<p>\"EVs are going from econo boxes to aspirational vehicles to the heart of the market,\" Brett Smith, technology director at Center for Automotive Research.</p>\n<p><b>ROTATING DASHBOARD SCREENS</b></p>\n<p>Tesla challengers are also betting on novel features such as a rotating dashboard screen in Fisker Ocean SUV to differentiate themselves from the pack.</p>\n<p>Henrik Fisker, chief executive of Fisker Inc, said the Ocean will be the first production car with a screen switching between its vertical and horizontal orientations.</p>\n<p>\"We filed a patent on it,\" he told Reuters, adding the screen will be supplied by Foxconn Technology Co Ltd, which will also produce Fisker's electric SUVs in the United States.</p>\n<p>\"I think it's going to appeal to a lot of young people who would love to play around on the screen. Also when you're sitting charging.\"</p>\n<p>Fisker and Vinfast also used the show to get on the radar with new models and bold claims that they say will have more affordable, and longer-range vehicles than Tesla's rival offerings.</p>\n<p>Tesla has become the world's most valuable automaker, with a market capitalization of more than $1 trillion, as it has redefined the electric vehicle market with sleek, high-tech cars and SUVs such as the Model Y that boasted longer driving ranges between charges than rival models.</p>\n<p>Tesla has taken advantage of its perceived technology edge and strong demand to lift prices for its vehicles, especially as prices for raw materials and semiconductors have risen this year.</p>\n<p>Rival EV makers see an opening.</p>\n<p>Vinfast global Chief Executive Michael Lohscheller, said its vehicles will have \"reasonable pricing,\" which is key to making people switch from gasoline cars to electric cars.</p>\n<p>Fisker said outsourcing production of models to Magna International has enabled the company to shorten development time and thus use the latest, long-range battery technology from supplier CATL.</p>\n<p>\"The technology is very new. Most other car makers, they choose their technologies three years before the vehicle comes out,\" he said.</p>\n<p>But it would be challenging for legacy automakers and startups to take on Tesla, which is \"synonymous with electric vehicles,\" said Smith.</p>\n<p>GM, Nissan have launched electric cars, but none of them have made a dent in Tesla's dominance, said Smith of Automotive Research. Scaling up EVs is another challenge, he added.</p>\n<p>\"The electric vehicle is opening the opportunity up to a lot of companies, regardless of where they come from,\" he said.</p>\n<p>\"Because Tesla did it doesn't mean it's easy, or others are going to do it.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>In Los Angeles, Tesla's rivals roll out larger, cheaper electric SUVs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIn Los Angeles, Tesla's rivals roll out larger, cheaper electric SUVs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-11-19 14:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LOS ANGELES, Nov 18 (Reuters) - Automakers chasing electric vehicle leader Tesla Inc&nbsp;revealed new, more affordable and larger electric sport utility vehicles at the Los Angeles Auto Show, racing into one of the fastest-growing segments of the U.S. market.</p>\n<p>Kia Motors&nbsp;called out Tesla by name at the show, announcing that its upcoming electric crossover EV6 beat Tesla’s previous record for the shortest charging time, while driving across the United States, by more than five hours.</p>\n<p>Kia and affiliate Hyundai Motor&nbsp;also unveiled large, three-row electric sport utility vehicle concepts, EV9 and SEVEN. These models are expected go into production around 2024, two persons familiar with the matter said.</p>\n<p>\"They (Tesla) have strong sales and they have a very good public awareness. But not everything is for everybody. So there should also always be an alternative,\" said Michael McHale, Kia's brand experience director.</p>\n<p>The focus on electric SUVs reflects the strong preference among U.S. consumers for SUVs, which typically sell for higher prices than similar-sized sedans. Large SUVs account for the top-selling segment in the U.S. market, industry executives and analysts have said.</p>\n<p>\"EVs are going from econo boxes to aspirational vehicles to the heart of the market,\" Brett Smith, technology director at Center for Automotive Research.</p>\n<p><b>ROTATING DASHBOARD SCREENS</b></p>\n<p>Tesla challengers are also betting on novel features such as a rotating dashboard screen in Fisker Ocean SUV to differentiate themselves from the pack.</p>\n<p>Henrik Fisker, chief executive of Fisker Inc, said the Ocean will be the first production car with a screen switching between its vertical and horizontal orientations.</p>\n<p>\"We filed a patent on it,\" he told Reuters, adding the screen will be supplied by Foxconn Technology Co Ltd, which will also produce Fisker's electric SUVs in the United States.</p>\n<p>\"I think it's going to appeal to a lot of young people who would love to play around on the screen. Also when you're sitting charging.\"</p>\n<p>Fisker and Vinfast also used the show to get on the radar with new models and bold claims that they say will have more affordable, and longer-range vehicles than Tesla's rival offerings.</p>\n<p>Tesla has become the world's most valuable automaker, with a market capitalization of more than $1 trillion, as it has redefined the electric vehicle market with sleek, high-tech cars and SUVs such as the Model Y that boasted longer driving ranges between charges than rival models.</p>\n<p>Tesla has taken advantage of its perceived technology edge and strong demand to lift prices for its vehicles, especially as prices for raw materials and semiconductors have risen this year.</p>\n<p>Rival EV makers see an opening.</p>\n<p>Vinfast global Chief Executive Michael Lohscheller, said its vehicles will have \"reasonable pricing,\" which is key to making people switch from gasoline cars to electric cars.</p>\n<p>Fisker said outsourcing production of models to Magna International has enabled the company to shorten development time and thus use the latest, long-range battery technology from supplier CATL.</p>\n<p>\"The technology is very new. Most other car makers, they choose their technologies three years before the vehicle comes out,\" he said.</p>\n<p>But it would be challenging for legacy automakers and startups to take on Tesla, which is \"synonymous with electric vehicles,\" said Smith.</p>\n<p>GM, Nissan have launched electric cars, but none of them have made a dent in Tesla's dominance, said Smith of Automotive Research. Scaling up EVs is another challenge, he added.</p>\n<p>\"The electric vehicle is opening the opportunity up to a lot of companies, regardless of where they come from,\" he said.</p>\n<p>\"Because Tesla did it doesn't mean it's easy, or others are going to do it.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4527":"明星科技股","BK4550":"红杉资本持仓","BK4555":"新能源车","BK4533":"AQR资本管理(全球第二大对冲基金)","FSR":"菲斯克","TSLA":"特斯拉","BK4099":"汽车制造商","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4534":"瑞士信贷持仓"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2184994048","content_text":"LOS ANGELES, Nov 18 (Reuters) - Automakers chasing electric vehicle leader Tesla Inc revealed new, more affordable and larger electric sport utility vehicles at the Los Angeles Auto Show, racing into one of the fastest-growing segments of the U.S. market.\nKia Motors called out Tesla by name at the show, announcing that its upcoming electric crossover EV6 beat Tesla’s previous record for the shortest charging time, while driving across the United States, by more than five hours.\nKia and affiliate Hyundai Motor also unveiled large, three-row electric sport utility vehicle concepts, EV9 and SEVEN. These models are expected go into production around 2024, two persons familiar with the matter said.\n\"They (Tesla) have strong sales and they have a very good public awareness. But not everything is for everybody. So there should also always be an alternative,\" said Michael McHale, Kia's brand experience director.\nThe focus on electric SUVs reflects the strong preference among U.S. consumers for SUVs, which typically sell for higher prices than similar-sized sedans. Large SUVs account for the top-selling segment in the U.S. market, industry executives and analysts have said.\n\"EVs are going from econo boxes to aspirational vehicles to the heart of the market,\" Brett Smith, technology director at Center for Automotive Research.\nROTATING DASHBOARD SCREENS\nTesla challengers are also betting on novel features such as a rotating dashboard screen in Fisker Ocean SUV to differentiate themselves from the pack.\nHenrik Fisker, chief executive of Fisker Inc, said the Ocean will be the first production car with a screen switching between its vertical and horizontal orientations.\n\"We filed a patent on it,\" he told Reuters, adding the screen will be supplied by Foxconn Technology Co Ltd, which will also produce Fisker's electric SUVs in the United States.\n\"I think it's going to appeal to a lot of young people who would love to play around on the screen. Also when you're sitting charging.\"\nFisker and Vinfast also used the show to get on the radar with new models and bold claims that they say will have more affordable, and longer-range vehicles than Tesla's rival offerings.\nTesla has become the world's most valuable automaker, with a market capitalization of more than $1 trillion, as it has redefined the electric vehicle market with sleek, high-tech cars and SUVs such as the Model Y that boasted longer driving ranges between charges than rival models.\nTesla has taken advantage of its perceived technology edge and strong demand to lift prices for its vehicles, especially as prices for raw materials and semiconductors have risen this year.\nRival EV makers see an opening.\nVinfast global Chief Executive Michael Lohscheller, said its vehicles will have \"reasonable pricing,\" which is key to making people switch from gasoline cars to electric cars.\nFisker said outsourcing production of models to Magna International has enabled the company to shorten development time and thus use the latest, long-range battery technology from supplier CATL.\n\"The technology is very new. Most other car makers, they choose their technologies three years before the vehicle comes out,\" he said.\nBut it would be challenging for legacy automakers and startups to take on Tesla, which is \"synonymous with electric vehicles,\" said Smith.\nGM, Nissan have launched electric cars, but none of them have made a dent in Tesla's dominance, said Smith of Automotive Research. Scaling up EVs is another challenge, he added.\n\"The electric vehicle is opening the opportunity up to a lot of companies, regardless of where they come from,\" he said.\n\"Because Tesla did it doesn't mean it's easy, or others are going to do it.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":479,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873980988,"gmtCreate":1636841899814,"gmtModify":1636841900156,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good news.....","listText":"Good news.....","text":"Good news.....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873980988","repostId":"1102251183","repostType":2,"repost":{"id":"1102251183","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":656,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879068524,"gmtCreate":1636671668556,"gmtModify":1636671669385,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","text":"$Tesla Motors(TSLA)$[看涨] [看涨] [看涨]","images":[{"img":"https://static.tigerbbs.com/32ceca53d53cc41a27dd706cc2c8723e","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879068524","isVote":1,"tweetType":1,"viewCount":779,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":870951479,"gmtCreate":1636583599657,"gmtModify":1636583648474,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","text":"$Tesla Motors(TSLA)$[看涨] [看涨] [看涨]","images":[{"img":"https://static.tigerbbs.com/abd8786d602813e2c19b9c1c1c32d38b","width":"1080","height":"2259"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870951479","isVote":1,"tweetType":1,"viewCount":532,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":847348082,"gmtCreate":1636497875885,"gmtModify":1636497876562,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Bad news for the market.&nbsp;","listText":"Bad news for the market.&nbsp;","text":"Bad news for the market.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/847348082","repostId":"1127189501","repostType":2,"repost":{"id":"1127189501","pubTimestamp":1636470995,"share":"https://www.laohu8.com/m/news/1127189501?lang=&edition=full","pubTime":"2021-11-09 23:16","market":"us","language":"en","title":"Kimbal Musk cashed out $109 million of Tesla stock just before Elon's tweets whacked the share price","url":"https://stock-news.laohu8.com/highlight/detail?id=1127189501","media":"businessinsider","summary":"Tesla board member Kimbal Musk sold around $109 million of the electric-car maker's stock shortly be","content":"<p>Tesla&nbsp;board member Kimbal Musk sold around $109 million of the electric-car maker's stock shortly before his brother Elon knocked the share price by asking Twitter if he should sell a big chunk of his holdings.</p>\n<p>Kimbal, an entrepreneur who sits on Tesla's board of directors, made a number of transactions on Friday according to a Securities and Exchange Commission&nbsp;filing.</p>\n<p>He exercised his stock options to buy 25,000 shares at just $74.17 a pop. Kimbal then sold 88,500 shares in a number of tranches at an average price of around $1,230, making him roughly $108.9 million.</p>\n<p>Elon's younger brother also donated 25,000 shares - which closed at $1,222.09 on Friday - to charity.</p>\n<p>Kimbal has not been the only director to take advantage of the Tesla's blistering rally, which has seen the stock price rise around 1,600% over the last two years.</p>\n<p>Filings&nbsp;from the end of October showed that directors Ira Ehrenpreis, Robyn Denholm and Antonio Gracias sold shares worth hundreds of millions of dollars.</p>\n<p>Tesla&nbsp;shares&nbsp;once&nbsp;fell&nbsp;nearly&nbsp;10%&nbsp;in&nbsp;morning&nbsp;trading.</p>","source":"lsy1636471102575","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kimbal Musk cashed out $109 million of Tesla stock just before Elon's tweets whacked the share price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKimbal Musk cashed out $109 million of Tesla stock just before Elon's tweets whacked the share price\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-09 23:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://markets.businessinsider.com/news/stocks/kimbal-musk-elon-tesla-stock-share-sale-twitter-poll-2021-11><strong>businessinsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tesla board member Kimbal Musk sold around $109 million of the electric-car maker's stock shortly before his brother Elon knocked the share price by asking Twitter if he should sell a big chunk of his...</p>\n\n<a href=\"https://markets.businessinsider.com/news/stocks/kimbal-musk-elon-tesla-stock-share-sale-twitter-poll-2021-11\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://markets.businessinsider.com/news/stocks/kimbal-musk-elon-tesla-stock-share-sale-twitter-poll-2021-11","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127189501","content_text":"Tesla board member Kimbal Musk sold around $109 million of the electric-car maker's stock shortly before his brother Elon knocked the share price by asking Twitter if he should sell a big chunk of his holdings.\nKimbal, an entrepreneur who sits on Tesla's board of directors, made a number of transactions on Friday according to a Securities and Exchange Commission filing.\nHe exercised his stock options to buy 25,000 shares at just $74.17 a pop. Kimbal then sold 88,500 shares in a number of tranches at an average price of around $1,230, making him roughly $108.9 million.\nElon's younger brother also donated 25,000 shares - which closed at $1,222.09 on Friday - to charity.\nKimbal has not been the only director to take advantage of the Tesla's blistering rally, which has seen the stock price rise around 1,600% over the last two years.\nFilings from the end of October showed that directors Ira Ehrenpreis, Robyn Denholm and Antonio Gracias sold shares worth hundreds of millions of dollars.\nTesla shares once fell nearly 10% in morning trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":823,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847366823,"gmtCreate":1636495044938,"gmtModify":1636495045706,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","text":"$Tesla Motors(TSLA)$[看涨] [看涨] [看涨]","images":[{"img":"https://static.tigerbbs.com/f2f53cce83b695dbeff08f53037b0bcd","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847366823","isVote":1,"tweetType":1,"viewCount":496,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":847004734,"gmtCreate":1636466289550,"gmtModify":1636466418494,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","text":"$Tesla Motors(TSLA)$[看涨] [看涨] [看涨]","images":[{"img":"https://static.tigerbbs.com/667477543e637a82db9490698f127c31","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847004734","isVote":1,"tweetType":1,"viewCount":211,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844117193,"gmtCreate":1636410815826,"gmtModify":1636410816521,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","text":"$Tesla Motors(TSLA)$[看涨] [看涨] [看涨]","images":[{"img":"https://static.tigerbbs.com/ed9dcbf9d7b5120fd12dca9f3bc99792","width":"1080","height":"2259"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844117193","isVote":1,"tweetType":1,"viewCount":179,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844322150,"gmtCreate":1636391797786,"gmtModify":1636391798498,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","text":"$Tesla Motors(TSLA)$[看涨] [看涨] [看涨]","images":[{"img":"https://static.tigerbbs.com/d1afe6769139e0cb6b2979b77f9fb458","width":"1080","height":"2172"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844322150","isVote":1,"tweetType":1,"viewCount":162,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":842101744,"gmtCreate":1636152342303,"gmtModify":1636152343127,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>[捂脸]&nbsp;I sold yesterday at $46.50....","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>[捂脸]&nbsp;I sold yesterday at $46.50....","text":"$Pfizer(PFE)$[捂脸] I sold yesterday at $46.50....","images":[{"img":"https://static.tigerbbs.com/591cb543ecb19b575998bfdc2edf29ee","width":"1080","height":"2259"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842101744","isVote":1,"tweetType":1,"viewCount":313,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":846198298,"gmtCreate":1636066216008,"gmtModify":1636066216786,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good news.","listText":"Good news.","text":"Good news.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846198298","repostId":"1198892706","repostType":4,"repost":{"id":"1198892706","pubTimestamp":1636039736,"share":"https://www.laohu8.com/m/news/1198892706?lang=&edition=full","pubTime":"2021-11-04 23:28","market":"us","language":"en","title":"US mandates vaccines or tests for big companies by Jan. 4","url":"https://stock-news.laohu8.com/highlight/detail?id=1198892706","media":"Associated Press News","summary":"Tens of millions of Americans who work at companies with 100 or more employees will need to be fully","content":"<p>Tens of millions of Americans who work at companies with 100 or more employees will need to be fully vaccinated against COVID-19 by Jan. 4 or get tested for the virus weekly under government rules issued Thursday.</p>\n<p>The new requirements, which were first previewed by President Joe Biden in September, will apply to about 84 million workers at medium and large businesses, although it is not clear how many of those employees are unvaccinated.</p>\n<p>The Occupational Safety and Health Administration regulations will force the companies to require that unvaccinated workers test negative for COVID-19 at least once a week and wear a mask while in the workplace.</p>\n<p>OSHA left open the possibility of expanding the requirement to smaller businesses. It asked for public comment on whether employers with fewer than 100 employees could handle vaccination or testing programs.</p>\n<p>Tougher rules will apply to another 17 million people who work in nursing homes, hospitals and other facilities that receive money from Medicare and Medicaid. Those workers will not have an option for testing — they will need to be vaccinated.</p>\n<p>Workers will be able to ask for exemptions on medical or religious grounds.</p>\n<p>OSHA said companies that fail to comply with the regulations could face penalties of nearly $14,000 per violation.</p>\n<p>It was unclear how OSHA planned to enforce the rules: Even counting allied regulators at the state level, the agency&nbsp;has only 1,850 inspectors&nbsp;to oversee 130 million workers at 8 million workplaces. A senior administration official said OSHA will target companies if it gets complaints.</p>\n<p>The release of the rules followed weeks of regulatory review and meetings with business groups, labor unions and others. The regulations form the cornerstone of Biden’s most aggressive effort yet to combat the spread of COVID-19, which has killed more than 740,000 people in the U.S.</p>\n<p>OSHA drafted the rules under emergency authority meant to protect workers from an imminent health hazard. The agency estimated that the vaccine mandate will save more than 6,500 worker lives and prevent more than 250,000 hospitalizations over the next six months.</p>\n<p>Senior administration officials said the rules preempt conflicting state laws or orders, including those that ban employers from requiring vaccinations, testing or the wearing of face masks.</p>\n<p>The administration will face an immediate challenge from Republican state officials who are eager to fight Biden in court and in Congress. Senate Republicans immediately launched a petition to force a vote to overturn the vaccine mandate, but with Democrats controlling the chamber, the effort is nearly certain to fail.</p>\n<p>More than two dozen Republicans serving as state attorneys general have indicated they plan to sue, arguing that only Congress can enact such sweeping requirements under emergency authority.</p>\n<p>Last week, 19 states sued to stop Biden’s narrower mandate that employees of federal contractors be vaccinated. That requirement was scheduled to take effect Dec. 8, but the administration said Thursday it will be delayed until Jan. 4 to match the requirements on other large employers and health care providers.</p>\n<p>The&nbsp;rules&nbsp;will require workers to receive either two doses of the Pfizer or Moderna vaccines or one dose of the Johnson &amp; Johnson vaccine by Jan. 4 or be tested weekly. Employees who test positive must be removed from the workplace.</p>\n<p>The requirements will not apply to people who work at home or outdoors.</p>\n<p>Companies won’t be required to provide or pay for the tests, but they must give paid time off for employees to get vaccines and sick leave to recover from side effects that prevent them from working. The requirements for masks and paid time off for shots will take effect Dec. 5.</p>\n<p>The Centers for Medicare &amp; Medicaid Services issued a separate rule requiring vaccination for workers in 76,000 health facilities and home health care providers that get funding from the government health programs. A senior administration official said that several large private health care organizations imposed their own mandates and achieved high vaccination rates — 96% or higher — without widespread resignations.</p>\n<p>The White House sees the new requirements as a potent tool to winnow down the ranks of the tens of millions of Americans who have thus far refused to get a shot.</p>\n<p>For weeks, Biden ha&nbsp;sencouraged businesses not to wait&nbsp;for the OSHA rule to take effect. He has touted businesses that have already announced their own vaccine mandates and urged other companies to follow their lead.</p>\n<p>Administration officials say those efforts are paying off, with about 70% of the nation’s adults now fully vaccinated.</p>\n<p>Walmart, the nation’s largest private employer, said in late July it was requiring all workers at its headquarters in Bentonville, Arkansas, as well as its managers who travel within the U.S., to be vaccinated against COVID-19 by Oct. 4. But the company had stopped short of requiring shots for its frontline workers.</p>\n<p>United Airlines required U.S. employees to get vaccinated or face termination. Only a very small number of its 67,000 workers refused to do so.</p>\n<p>In August, Tyson Foods told its 120,000 U.S. workers that they must be vaccinated by Nov. 1. A week before that deadline, the company said 96% of its workforce was fully vaccinated.</p>\n<p>However, some companies have expressed fear that some vaccine-hesitant workers might quit, leaving their workforces even thinner in what is already a tight labor market.</p>\n<p>Several large business groups complained about the timing of the mandate. Retail groups worried that the requirement could disrupt their operations during the critical Christmas shopping period. Retailers and others also said it could worsen supply chain disruptions.</p>\n<p>The National Retail Federation suggested that the new rules are not needed because the rolling average number of new daily cases in the U.S. has fallen by more than half since September.</p>\n<p>“Nevertheless, the Biden administration has chosen to declare an ‘emergency’ and impose burdensome new requirements on retailers during the crucial holiday shopping season,” said David French, a senior vice president for the trade group.</p>\n<p>The number of new COVID-19 infections in the U.S. is still falling from a summer surge caused by the highly contagious delta variant, but the rate of decline has slowed in recent weeks. The 7-day moving average is down 6% from two weeks ago, at more than 76,000 new cases and 1,200 deaths per day.</p>\n<p>The earlier mandate on federal contractors led to demonstrations by opponents, including workers at a NASA rocket engine test site in Mississippi. Some said they are immune because they contracted COVID-19. Others said vaccines violated their religious beliefs and constitutional rights.</p>\n<p>“No one should be forced to take a medical treatment just to keep their job,” said Nyla Trumbach, an engineer at the site. “There’s years and years of experience and skill out here, and I just want anyone who’s watching to see what we stand to lose here if these people don’t keep their jobs.”</p>\n<p>Dozens of groups sought meetings with administration officials toair their concernsand objections to likely provisions of the OSHA rule, including the U.S. Chamber of Commerce, the National Association of Manufacturers, the AFL-CIO and anti-vaccine organizations.</p>","source":"lsy1603278176698","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US mandates vaccines or tests for big companies by Jan. 4</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS mandates vaccines or tests for big companies by Jan. 4\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-04 23:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://apnews.com/article/covid-employer-mandates-us-29c2262c336bcfc38da2d14b251daf51><strong>Associated Press News</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tens of millions of Americans who work at companies with 100 or more employees will need to be fully vaccinated against COVID-19 by Jan. 4 or get tested for the virus weekly under government rules ...</p>\n\n<a href=\"https://apnews.com/article/covid-employer-mandates-us-29c2262c336bcfc38da2d14b251daf51\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://apnews.com/article/covid-employer-mandates-us-29c2262c336bcfc38da2d14b251daf51","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198892706","content_text":"Tens of millions of Americans who work at companies with 100 or more employees will need to be fully vaccinated against COVID-19 by Jan. 4 or get tested for the virus weekly under government rules issued Thursday.\nThe new requirements, which were first previewed by President Joe Biden in September, will apply to about 84 million workers at medium and large businesses, although it is not clear how many of those employees are unvaccinated.\nThe Occupational Safety and Health Administration regulations will force the companies to require that unvaccinated workers test negative for COVID-19 at least once a week and wear a mask while in the workplace.\nOSHA left open the possibility of expanding the requirement to smaller businesses. It asked for public comment on whether employers with fewer than 100 employees could handle vaccination or testing programs.\nTougher rules will apply to another 17 million people who work in nursing homes, hospitals and other facilities that receive money from Medicare and Medicaid. Those workers will not have an option for testing — they will need to be vaccinated.\nWorkers will be able to ask for exemptions on medical or religious grounds.\nOSHA said companies that fail to comply with the regulations could face penalties of nearly $14,000 per violation.\nIt was unclear how OSHA planned to enforce the rules: Even counting allied regulators at the state level, the agency has only 1,850 inspectors to oversee 130 million workers at 8 million workplaces. A senior administration official said OSHA will target companies if it gets complaints.\nThe release of the rules followed weeks of regulatory review and meetings with business groups, labor unions and others. The regulations form the cornerstone of Biden’s most aggressive effort yet to combat the spread of COVID-19, which has killed more than 740,000 people in the U.S.\nOSHA drafted the rules under emergency authority meant to protect workers from an imminent health hazard. The agency estimated that the vaccine mandate will save more than 6,500 worker lives and prevent more than 250,000 hospitalizations over the next six months.\nSenior administration officials said the rules preempt conflicting state laws or orders, including those that ban employers from requiring vaccinations, testing or the wearing of face masks.\nThe administration will face an immediate challenge from Republican state officials who are eager to fight Biden in court and in Congress. Senate Republicans immediately launched a petition to force a vote to overturn the vaccine mandate, but with Democrats controlling the chamber, the effort is nearly certain to fail.\nMore than two dozen Republicans serving as state attorneys general have indicated they plan to sue, arguing that only Congress can enact such sweeping requirements under emergency authority.\nLast week, 19 states sued to stop Biden’s narrower mandate that employees of federal contractors be vaccinated. That requirement was scheduled to take effect Dec. 8, but the administration said Thursday it will be delayed until Jan. 4 to match the requirements on other large employers and health care providers.\nThe rules will require workers to receive either two doses of the Pfizer or Moderna vaccines or one dose of the Johnson & Johnson vaccine by Jan. 4 or be tested weekly. Employees who test positive must be removed from the workplace.\nThe requirements will not apply to people who work at home or outdoors.\nCompanies won’t be required to provide or pay for the tests, but they must give paid time off for employees to get vaccines and sick leave to recover from side effects that prevent them from working. The requirements for masks and paid time off for shots will take effect Dec. 5.\nThe Centers for Medicare & Medicaid Services issued a separate rule requiring vaccination for workers in 76,000 health facilities and home health care providers that get funding from the government health programs. A senior administration official said that several large private health care organizations imposed their own mandates and achieved high vaccination rates — 96% or higher — without widespread resignations.\nThe White House sees the new requirements as a potent tool to winnow down the ranks of the tens of millions of Americans who have thus far refused to get a shot.\nFor weeks, Biden ha sencouraged businesses not to wait for the OSHA rule to take effect. He has touted businesses that have already announced their own vaccine mandates and urged other companies to follow their lead.\nAdministration officials say those efforts are paying off, with about 70% of the nation’s adults now fully vaccinated.\nWalmart, the nation’s largest private employer, said in late July it was requiring all workers at its headquarters in Bentonville, Arkansas, as well as its managers who travel within the U.S., to be vaccinated against COVID-19 by Oct. 4. But the company had stopped short of requiring shots for its frontline workers.\nUnited Airlines required U.S. employees to get vaccinated or face termination. Only a very small number of its 67,000 workers refused to do so.\nIn August, Tyson Foods told its 120,000 U.S. workers that they must be vaccinated by Nov. 1. A week before that deadline, the company said 96% of its workforce was fully vaccinated.\nHowever, some companies have expressed fear that some vaccine-hesitant workers might quit, leaving their workforces even thinner in what is already a tight labor market.\nSeveral large business groups complained about the timing of the mandate. Retail groups worried that the requirement could disrupt their operations during the critical Christmas shopping period. Retailers and others also said it could worsen supply chain disruptions.\nThe National Retail Federation suggested that the new rules are not needed because the rolling average number of new daily cases in the U.S. has fallen by more than half since September.\n“Nevertheless, the Biden administration has chosen to declare an ‘emergency’ and impose burdensome new requirements on retailers during the crucial holiday shopping season,” said David French, a senior vice president for the trade group.\nThe number of new COVID-19 infections in the U.S. is still falling from a summer surge caused by the highly contagious delta variant, but the rate of decline has slowed in recent weeks. The 7-day moving average is down 6% from two weeks ago, at more than 76,000 new cases and 1,200 deaths per day.\nThe earlier mandate on federal contractors led to demonstrations by opponents, including workers at a NASA rocket engine test site in Mississippi. Some said they are immune because they contracted COVID-19. Others said vaccines violated their religious beliefs and constitutional rights.\n“No one should be forced to take a medical treatment just to keep their job,” said Nyla Trumbach, an engineer at the site. “There’s years and years of experience and skill out here, and I just want anyone who’s watching to see what we stand to lose here if these people don’t keep their jobs.”\nDozens of groups sought meetings with administration officials toair their concernsand objections to likely provisions of the OSHA rule, including the U.S. Chamber of Commerce, the National Association of Manufacturers, the AFL-CIO and anti-vaccine organizations.","news_type":1},"isVote":1,"tweetType":1,"viewCount":121,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846193570,"gmtCreate":1636066084373,"gmtModify":1636066085057,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>[看跌]&nbsp;[看跌]&nbsp;[看跌]&nbsp;","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>[看跌]&nbsp;[看跌]&nbsp;[看跌]&nbsp;","text":"$Pfizer(PFE)$[看跌] [看跌] [看跌]","images":[{"img":"https://static.tigerbbs.com/6af65a7651d317e785a48463737da5d3","width":"1080","height":"2259"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846193570","isVote":1,"tweetType":1,"viewCount":268,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":841386631,"gmtCreate":1635889023153,"gmtModify":1635889023379,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>sold at$ $45.65","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>sold at$ $45.65","text":"$Pfizer(PFE)$sold at$ $45.65","images":[{"img":"https://static.tigerbbs.com/b3c90cc907a822d84b0f6faa7b45a9d1","width":"1080","height":"2259"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841386631","isVote":1,"tweetType":1,"viewCount":177,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":843967103,"gmtCreate":1635802490398,"gmtModify":1635802490608,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[捂脸]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[捂脸]&nbsp;","text":"$Tesla Motors(TSLA)$[捂脸]","images":[{"img":"https://static.tigerbbs.com/e49c37c0bc271f97347002e0bf7a52d6","width":"1080","height":"2259"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843967103","isVote":1,"tweetType":1,"viewCount":263,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":843967053,"gmtCreate":1635802465903,"gmtModify":1635802466154,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","text":"$Pfizer(PFE)$[看涨] [看涨] [看涨]","images":[{"img":"https://static.tigerbbs.com/d0507d4934b9dce7552ec60c25d30ec6","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843967053","isVote":1,"tweetType":1,"viewCount":297,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":849614661,"gmtCreate":1635751608169,"gmtModify":1635751608398,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","text":"$Pfizer(PFE)$[看涨] [看涨] [看涨]","images":[{"img":"https://static.tigerbbs.com/2598c8ee72a06044f6b7b3c171fb0c26","width":"1080","height":"2259"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849614661","isVote":1,"tweetType":1,"viewCount":147,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"hots":[{"id":187434860,"gmtCreate":1623761586250,"gmtModify":1631892957542,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","text":"$Apple(AAPL)$[看涨] [看涨] [看涨]","images":[{"img":"https://static.tigerbbs.com/210d4ca9a62ba8be068a7e025a736737","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":1,"link":"https://laohu8.com/post/187434860","isVote":1,"tweetType":1,"viewCount":62,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":133182445,"gmtCreate":1621728085387,"gmtModify":1631892957553,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>[捂脸]&nbsp;[流泪]&nbsp;when is it going to move up????","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>[捂脸]&nbsp;[流泪]&nbsp;when is it going to move up????","text":"$Apple(AAPL)$[捂脸] [流泪] when is it going to move up????","images":[{"img":"https://static.tigerbbs.com/af1ce2b0ef4b78dcf19ba7553e64c1d3","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/133182445","isVote":1,"tweetType":1,"viewCount":291,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":801859602,"gmtCreate":1627511221106,"gmtModify":1631892957581,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","text":"$Pfizer(PFE)$[看涨] [看涨] [看涨]","images":[{"img":"https://static.tigerbbs.com/a4090ca8f47bc1dfb4cac87b877e8a69","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/801859602","isVote":1,"tweetType":1,"viewCount":130,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":121313749,"gmtCreate":1624453568181,"gmtModify":1631892957589,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","text":"$Pfizer(PFE)$[看涨] [看涨] [看涨]","images":[{"img":"https://static.tigerbbs.com/6a32bb65cb61ddd7bb7f8e0bbb1e6e92","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/121313749","isVote":1,"tweetType":1,"viewCount":131,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":847348082,"gmtCreate":1636497875885,"gmtModify":1636497876562,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Bad news for the market.&nbsp;","listText":"Bad news for the market.&nbsp;","text":"Bad news for the market.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/847348082","repostId":"1127189501","repostType":2,"repost":{"id":"1127189501","pubTimestamp":1636470995,"share":"https://www.laohu8.com/m/news/1127189501?lang=&edition=full","pubTime":"2021-11-09 23:16","market":"us","language":"en","title":"Kimbal Musk cashed out $109 million of Tesla stock just before Elon's tweets whacked the share price","url":"https://stock-news.laohu8.com/highlight/detail?id=1127189501","media":"businessinsider","summary":"Tesla board member Kimbal Musk sold around $109 million of the electric-car maker's stock shortly be","content":"<p>Tesla&nbsp;board member Kimbal Musk sold around $109 million of the electric-car maker's stock shortly before his brother Elon knocked the share price by asking Twitter if he should sell a big chunk of his holdings.</p>\n<p>Kimbal, an entrepreneur who sits on Tesla's board of directors, made a number of transactions on Friday according to a Securities and Exchange Commission&nbsp;filing.</p>\n<p>He exercised his stock options to buy 25,000 shares at just $74.17 a pop. Kimbal then sold 88,500 shares in a number of tranches at an average price of around $1,230, making him roughly $108.9 million.</p>\n<p>Elon's younger brother also donated 25,000 shares - which closed at $1,222.09 on Friday - to charity.</p>\n<p>Kimbal has not been the only director to take advantage of the Tesla's blistering rally, which has seen the stock price rise around 1,600% over the last two years.</p>\n<p>Filings&nbsp;from the end of October showed that directors Ira Ehrenpreis, Robyn Denholm and Antonio Gracias sold shares worth hundreds of millions of dollars.</p>\n<p>Tesla&nbsp;shares&nbsp;once&nbsp;fell&nbsp;nearly&nbsp;10%&nbsp;in&nbsp;morning&nbsp;trading.</p>","source":"lsy1636471102575","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kimbal Musk cashed out $109 million of Tesla stock just before Elon's tweets whacked the share price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKimbal Musk cashed out $109 million of Tesla stock just before Elon's tweets whacked the share price\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-09 23:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://markets.businessinsider.com/news/stocks/kimbal-musk-elon-tesla-stock-share-sale-twitter-poll-2021-11><strong>businessinsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tesla board member Kimbal Musk sold around $109 million of the electric-car maker's stock shortly before his brother Elon knocked the share price by asking Twitter if he should sell a big chunk of his...</p>\n\n<a href=\"https://markets.businessinsider.com/news/stocks/kimbal-musk-elon-tesla-stock-share-sale-twitter-poll-2021-11\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://markets.businessinsider.com/news/stocks/kimbal-musk-elon-tesla-stock-share-sale-twitter-poll-2021-11","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127189501","content_text":"Tesla board member Kimbal Musk sold around $109 million of the electric-car maker's stock shortly before his brother Elon knocked the share price by asking Twitter if he should sell a big chunk of his holdings.\nKimbal, an entrepreneur who sits on Tesla's board of directors, made a number of transactions on Friday according to a Securities and Exchange Commission filing.\nHe exercised his stock options to buy 25,000 shares at just $74.17 a pop. Kimbal then sold 88,500 shares in a number of tranches at an average price of around $1,230, making him roughly $108.9 million.\nElon's younger brother also donated 25,000 shares - which closed at $1,222.09 on Friday - to charity.\nKimbal has not been the only director to take advantage of the Tesla's blistering rally, which has seen the stock price rise around 1,600% over the last two years.\nFilings from the end of October showed that directors Ira Ehrenpreis, Robyn Denholm and Antonio Gracias sold shares worth hundreds of millions of dollars.\nTesla shares once fell nearly 10% in morning trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":823,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":832202776,"gmtCreate":1629633013995,"gmtModify":1631892957600,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[惊讶]&nbsp;[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","listText":"[惊讶]&nbsp;[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","text":"[惊讶] [看涨] [看涨] [看涨]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/832202776","repostId":"1133515985","repostType":2,"isVote":1,"tweetType":1,"viewCount":155,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":831108223,"gmtCreate":1629293476662,"gmtModify":1631885478904,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INTC\">$Intel(INTC)$</a>[捂脸]&nbsp;[捂脸]&nbsp;[喷血]&nbsp;","listText":"<a href=\"https://laohu8.com/S/INTC\">$Intel(INTC)$</a>[捂脸]&nbsp;[捂脸]&nbsp;[喷血]&nbsp;","text":"$Intel(INTC)$[捂脸] [捂脸] [喷血]","images":[{"img":"https://static.tigerbbs.com/3be4c87466dde024c5f669660c455424","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":1,"link":"https://laohu8.com/post/831108223","isVote":1,"tweetType":1,"viewCount":115,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":158440346,"gmtCreate":1625178888085,"gmtModify":1631892957625,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>[贱笑]&nbsp;[贱笑]&nbsp;[贱笑]&nbsp;","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>[贱笑]&nbsp;[贱笑]&nbsp;[贱笑]&nbsp;","text":"$Pfizer(PFE)$[贱笑] [贱笑] [贱笑]","images":[{"img":"https://static.tigerbbs.com/bb173f780ecfd46e039f5f4768ce57fa","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/158440346","isVote":1,"tweetType":1,"viewCount":112,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":182511091,"gmtCreate":1623587998913,"gmtModify":1631892957637,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>[冷漠]&nbsp;[冷漠]&nbsp;[冷漠]&nbsp;","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>[冷漠]&nbsp;[冷漠]&nbsp;[冷漠]&nbsp;","text":"$Apple(AAPL)$[冷漠] [冷漠] [冷漠]","images":[{"img":"https://static.tigerbbs.com/97ddbd61247e4b42c489947060b63ea7","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":1,"link":"https://laohu8.com/post/182511091","isVote":1,"tweetType":1,"viewCount":77,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":873980988,"gmtCreate":1636841899814,"gmtModify":1636841900156,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good news.....","listText":"Good news.....","text":"Good news.....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873980988","repostId":"1102251183","repostType":2,"repost":{"id":"1102251183","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":656,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847366823,"gmtCreate":1636495044938,"gmtModify":1636495045706,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","text":"$Tesla Motors(TSLA)$[看涨] [看涨] [看涨]","images":[{"img":"https://static.tigerbbs.com/f2f53cce83b695dbeff08f53037b0bcd","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847366823","isVote":1,"tweetType":1,"viewCount":496,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":814110407,"gmtCreate":1630794545509,"gmtModify":1631883903339,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","text":"$Pfizer(PFE)$[看涨] [看涨] [看涨]","images":[{"img":"https://static.tigerbbs.com/fb2cfe485bb4f70d9c8993272f9ba17c","width":"1080","height":"2259"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/814110407","isVote":1,"tweetType":1,"viewCount":94,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":839374525,"gmtCreate":1629124491867,"gmtModify":1631885478937,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INTC\">$Intel(INTC)$</a>[捂脸]&nbsp;[喷血]&nbsp;","listText":"<a href=\"https://laohu8.com/S/INTC\">$Intel(INTC)$</a>[捂脸]&nbsp;[喷血]&nbsp;","text":"$Intel(INTC)$[捂脸] [喷血]","images":[{"img":"https://static.tigerbbs.com/dec3ac77b54e5aec96519c5885beef71","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/839374525","isVote":1,"tweetType":1,"viewCount":47,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":892921624,"gmtCreate":1628635584968,"gmtModify":1631885479078,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INTC\">$Intel(INTC)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","listText":"<a href=\"https://laohu8.com/S/INTC\">$Intel(INTC)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","text":"$Intel(INTC)$[看涨] [看涨] [看涨]","images":[{"img":"https://static.tigerbbs.com/c9c8889ce290979a1db388b539ed51af","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/892921624","isVote":1,"tweetType":1,"viewCount":128,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":803172522,"gmtCreate":1627430007166,"gmtModify":1631892957645,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;fingers crossed....","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;fingers crossed....","text":"$Pfizer(PFE)$[看涨] [看涨] [看涨] fingers crossed....","images":[{"img":"https://static.tigerbbs.com/578913f5f0062c9807047ff0d2426575","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/803172522","isVote":1,"tweetType":1,"viewCount":155,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":130675697,"gmtCreate":1621549660519,"gmtModify":1631892957670,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[无语]&nbsp;","listText":"[无语]&nbsp;","text":"[无语]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/130675697","repostId":"1180231636","repostType":2,"repost":{"id":"1180231636","pubTimestamp":1621523836,"share":"https://www.laohu8.com/m/news/1180231636?lang=&edition=full","pubTime":"2021-05-20 23:17","market":"us","language":"en","title":"Apple: Victim Of Its Own Success","url":"https://stock-news.laohu8.com/highlight/detail?id=1180231636","media":"seekingalpha","summary":"Summary\n\nInvestors will likely fret over revenue growth rates later this year.\nRegular iPhone launch","content":"<p><b>Summary</b></p>\n<ul>\n <li>Investors will likely fret over revenue growth rates later this year.</li>\n <li>Regular iPhone launch timing could pull forward meaningful sales.</li>\n <li>As stock stays flat, buyback can become more powerful.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cd9ae225cce8f1aea80db542b535f742\" tg-width=\"768\" tg-height=\"512\"><span>Photo by Paopano/iStock Editorial via Getty Images</span></p>\n<p>Technology giant Apple (AAPL) reported&nbsp;a massive earnings blowout&nbsp;a few weeks ago, and the numbers were truly staggering. A company of this size reporting revenue growth of more than 53% over the prior year period was truly remarkable. Yes, the company has benefited from soft earlier year comparisons and the work from home tailwinds, but you can't argue that its products are not in high demand. As great as Apple's numbers have been lately, it might prove to be a risk later this year.</p>\n<p>I am saying today that Apple could be a victim of its own success because the stock market is always a what have you done for me lately crowd. As the chart below shows, the high revenue growth rates we'll see are expected to come crashing down once we hit the December quarter (fiscal Q1 2022). That 53% growth figure for the March 2021 quarter sets up an insanely high bar that analysts don't think can be repeated next year. Blue bars are actual results, while green ones are current street average estimates.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2b61b66cfb83a8e7f307580dd6277be6\" tg-width=\"625\" tg-height=\"397\"><span>(Source: Seeking Alpha estimates page)</span></p>\n<p>I'm sure the Apple bear crowd will be out in full force if Apple guides to or reports a revenue decline for fiscal Q2 2022. Of course, a small top line decline then would still be a tremendous quarter when looking at the longer term picture. Even though analysts are currently looking for a 2.2% revenue decline in that March 2022 quarter, the average revenue estimate for that period has risen by nearly 16% over the past six months, for example. Over the past year, the average is up by almost $20 billion.</p>\n<p>Apple has been helped by the coronavirus in the short term, not only from the work from home crowd buying more tablets and computers, but by the massive stimulus provided by global governments. While those tailwinds will calm down in the coming quarters, economies should be doing better so consumer spending should remain fairly decent. Even though central banks may start to tighten their monetary policy a little, they are certainly not going to do anything severe that will crash things again.</p>\n<p>The other issue for Apple regarding the coronavirus was the timing of major launches. With factories shut down for a time in 2020, the iPhone release schedule for last year changed in a meaningful way. Instead of seeing one or more phones available to consumers in September, two iPhone 12 models went on sale in late October, with the other two in mid-November. If Apple returns to a normal schedule this year, it will pull billions of revenue forward into the September 2021 (fiscal Q4) quarter. That could further make the early 2022 comparisons tougher to match, giving more fuel to the bears.</p>\n<p>When Apple has a big sales year, like it is having with the iPhone currently, investors worry that the next cycle won't be as strong in terms of unit sales. I'm not as concerned this time around with that, partially because consumers are going to want and need to upgrade to 5G smartphones, and that should fuel a multi-year upgrade period. The other thing that could help is if Apple follows what it did with the iPad Pro launch from earlier this year. Take a look at the following table which shows the initial pricing of the larger screen Pro tablet version over the years. There are also the Cellular models that will cost a little bit more, but for this argument, I'm only showing the base Wi-Fi model.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f77225da409fee0ad2e69fb1c32c2505\" tg-width=\"640\" tg-height=\"107\"><span>(Source: iPad Pro wikipedia page)</span></p>\n<p>Because of both the advancements in technology as well as larger storage, Apple has raised prices significantly over the years. The most expensive version of this tablet has doubled in price since 2015, and the three lowest storage versions are up $100 each over their prior year counterpart. Thus, if you are arguing that iPad unit sales may be down 5-10% a year from now, it may not be a big deal if Apple is seeing average selling prices that are up 15-20% over that time. I could see a similar thing happening with the iPhone this year, depending on how many older generations stick around and whether or not Apple launches a 1 TB storage option for the smartphone.</p>\n<p>Even if Apple's results aren't as tremendous as some hope they might be moving forward, this company is still doing incredibly well. Free cash flow could be well over $80 billion this year, allowing for a dividend and huge buyback. Don't forget that as shares stay around this $125 level, the repurchasing of shares becomes more significant each quarter as the share count comes down. $20 billion in buybacks every three months at a $2.1 trillion market cap does more than at a $2.2 trillion valuation, for example, and earnings per share will continue to benefit.</p>\n<p>Wednesday was another important day for Apple. With the market dropping at the open, Apple fell below its 200-day moving average (green line below). However, the stock was able to regain this key technical level and close above it. As the chart below shows, shares are currently stuck between the 50 and 200-day moving averages, and both lines are mostly flat at this point. Should the stock be able to get back above the shorter term trend line, it could provide a level of support moving forward.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/de8ca788fa86bda735f874b66546312a\" tg-width=\"640\" tg-height=\"273\"><span>(Source: Yahoo! Finance)</span></p>\n<p>In the end, Apple may become a victim of its own success rather soon. Two massive blowout quarters have not only sent analyst estimates through the roof, but set high bars for future quarters. While the company's sales will remain in an uptrend over the long term, I'm sure the bears will surface if the top line is forecast to decline, especially if a normal iPhone launch pulls sales forward. For now, Apple shares are looking for direction, with investors hoping the stock can regain the 50-day moving average and start a new breakout.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple: Victim Of Its Own Success</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple: Victim Of Its Own Success\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-20 23:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4430161-apple-victim-of-its-own-success><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nInvestors will likely fret over revenue growth rates later this year.\nRegular iPhone launch timing could pull forward meaningful sales.\nAs stock stays flat, buyback can become more powerful.\n...</p>\n\n<a href=\"https://seekingalpha.com/article/4430161-apple-victim-of-its-own-success\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://seekingalpha.com/article/4430161-apple-victim-of-its-own-success","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1180231636","content_text":"Summary\n\nInvestors will likely fret over revenue growth rates later this year.\nRegular iPhone launch timing could pull forward meaningful sales.\nAs stock stays flat, buyback can become more powerful.\n\nPhoto by Paopano/iStock Editorial via Getty Images\nTechnology giant Apple (AAPL) reported a massive earnings blowout a few weeks ago, and the numbers were truly staggering. A company of this size reporting revenue growth of more than 53% over the prior year period was truly remarkable. Yes, the company has benefited from soft earlier year comparisons and the work from home tailwinds, but you can't argue that its products are not in high demand. As great as Apple's numbers have been lately, it might prove to be a risk later this year.\nI am saying today that Apple could be a victim of its own success because the stock market is always a what have you done for me lately crowd. As the chart below shows, the high revenue growth rates we'll see are expected to come crashing down once we hit the December quarter (fiscal Q1 2022). That 53% growth figure for the March 2021 quarter sets up an insanely high bar that analysts don't think can be repeated next year. Blue bars are actual results, while green ones are current street average estimates.\n(Source: Seeking Alpha estimates page)\nI'm sure the Apple bear crowd will be out in full force if Apple guides to or reports a revenue decline for fiscal Q2 2022. Of course, a small top line decline then would still be a tremendous quarter when looking at the longer term picture. Even though analysts are currently looking for a 2.2% revenue decline in that March 2022 quarter, the average revenue estimate for that period has risen by nearly 16% over the past six months, for example. Over the past year, the average is up by almost $20 billion.\nApple has been helped by the coronavirus in the short term, not only from the work from home crowd buying more tablets and computers, but by the massive stimulus provided by global governments. While those tailwinds will calm down in the coming quarters, economies should be doing better so consumer spending should remain fairly decent. Even though central banks may start to tighten their monetary policy a little, they are certainly not going to do anything severe that will crash things again.\nThe other issue for Apple regarding the coronavirus was the timing of major launches. With factories shut down for a time in 2020, the iPhone release schedule for last year changed in a meaningful way. Instead of seeing one or more phones available to consumers in September, two iPhone 12 models went on sale in late October, with the other two in mid-November. If Apple returns to a normal schedule this year, it will pull billions of revenue forward into the September 2021 (fiscal Q4) quarter. That could further make the early 2022 comparisons tougher to match, giving more fuel to the bears.\nWhen Apple has a big sales year, like it is having with the iPhone currently, investors worry that the next cycle won't be as strong in terms of unit sales. I'm not as concerned this time around with that, partially because consumers are going to want and need to upgrade to 5G smartphones, and that should fuel a multi-year upgrade period. The other thing that could help is if Apple follows what it did with the iPad Pro launch from earlier this year. Take a look at the following table which shows the initial pricing of the larger screen Pro tablet version over the years. There are also the Cellular models that will cost a little bit more, but for this argument, I'm only showing the base Wi-Fi model.\n(Source: iPad Pro wikipedia page)\nBecause of both the advancements in technology as well as larger storage, Apple has raised prices significantly over the years. The most expensive version of this tablet has doubled in price since 2015, and the three lowest storage versions are up $100 each over their prior year counterpart. Thus, if you are arguing that iPad unit sales may be down 5-10% a year from now, it may not be a big deal if Apple is seeing average selling prices that are up 15-20% over that time. I could see a similar thing happening with the iPhone this year, depending on how many older generations stick around and whether or not Apple launches a 1 TB storage option for the smartphone.\nEven if Apple's results aren't as tremendous as some hope they might be moving forward, this company is still doing incredibly well. Free cash flow could be well over $80 billion this year, allowing for a dividend and huge buyback. Don't forget that as shares stay around this $125 level, the repurchasing of shares becomes more significant each quarter as the share count comes down. $20 billion in buybacks every three months at a $2.1 trillion market cap does more than at a $2.2 trillion valuation, for example, and earnings per share will continue to benefit.\nWednesday was another important day for Apple. With the market dropping at the open, Apple fell below its 200-day moving average (green line below). However, the stock was able to regain this key technical level and close above it. As the chart below shows, shares are currently stuck between the 50 and 200-day moving averages, and both lines are mostly flat at this point. Should the stock be able to get back above the shorter term trend line, it could provide a level of support moving forward.\n(Source: Yahoo! Finance)\nIn the end, Apple may become a victim of its own success rather soon. Two massive blowout quarters have not only sent analyst estimates through the roof, but set high bars for future quarters. While the company's sales will remain in an uptrend over the long term, I'm sure the bears will surface if the top line is forecast to decline, especially if a normal iPhone launch pulls sales forward. For now, Apple shares are looking for direction, with investors hoping the stock can regain the 50-day moving average and start a new breakout.","news_type":1},"isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":105483298,"gmtCreate":1620316571314,"gmtModify":1631892957517,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>[笑哭]&nbsp;","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>[笑哭]&nbsp;","text":"$Pfizer(PFE)$[笑哭]","images":[{"img":"https://static.tigerbbs.com/9308172464b4085ff0bb7bce0c733957","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/105483298","isVote":1,"tweetType":1,"viewCount":322,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":879068524,"gmtCreate":1636671668556,"gmtModify":1636671669385,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;","text":"$Tesla Motors(TSLA)$[看涨] [看涨] [看涨]","images":[{"img":"https://static.tigerbbs.com/32ceca53d53cc41a27dd706cc2c8723e","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879068524","isVote":1,"tweetType":1,"viewCount":779,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":846198298,"gmtCreate":1636066216008,"gmtModify":1636066216786,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good news.","listText":"Good news.","text":"Good news.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846198298","repostId":"1198892706","repostType":4,"isVote":1,"tweetType":1,"viewCount":121,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":869031507,"gmtCreate":1632226207709,"gmtModify":1632801967695,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INTC\">$Intel(INTC)$</a>time to buy???[白眼]&nbsp;","listText":"<a href=\"https://laohu8.com/S/INTC\">$Intel(INTC)$</a>time to buy???[白眼]&nbsp;","text":"$Intel(INTC)$time to buy???[白眼]","images":[{"img":"https://static.tigerbbs.com/bbc21f971ece8c93767bf7b71b42f073","width":"1080","height":"2259"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/869031507","isVote":1,"tweetType":1,"viewCount":172,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"lives":[]}